P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits
This article was originally published in The Tan Sheet
Executive Summary
A P&G petition revives the firm’s argument that future OTC proton pump inhibitors should be held to the same labeling language as Prilosec OTC. The firm also argues that the NDA process can allow labeling that unfairly gives some products marketplace advantages over category competitors.
You may also be interested in...
Pfizer Expects OTC Nexium Will Launch With Market Exclusivity
Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.
Pfizer Expects OTC Nexium Will Launch With Market Exclusivity
Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.
Major OTC Acquisitions, Expansion Likely In 2014
With major consumer product divisions potentially in play, analysts take a look at possible buyers and sellers in the OTC space. Switches and consumer business expansion plans are also likely to shape 2014.